New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
10:07 EDTAGN, VAR, ETFC, AMTD, SCHW, CHMT, ALKSOn The Fly: Analysts Initiation Summary
Today's noteworthy initiations include: Allergan (AGN) initiated with a Buy at SunTrust...Varian Medical (VAR) initiated with a Buy at Benchmark Co. and with a Buy at SunTrust...E-Trade (ETFC) initiated with a Neutral at Compass Point...TD Ameritrade (AMTD) initiated with a Neutral at Compass Point...Charles Schwab (SCHW) initiated with a Neutral at Compass Point...Chemtura (CHMT) initiated with a Buy at KeyBanc...Alkermes (ALKS) initiated with a Buy at Mizuho.
News For AGN;VAR;ETFC;AMTD;SCHW;CHMT;ALKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 20, 2014
06:28 EDTAGNAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 17, 2014
09:47 EDTAGNValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:45 EDTAGNAllergan not in deal talks with Actavis, CNBC reports
09:43 EDTAGNValeant not going to raise Allergan bid ahead of meeting, CNBC reports
Subscribe for More Information
October 16, 2014
12:42 EDTAGNAckman believes Allergan, Valeant merger likely, CNBC reports
Subscribe for More Information
12:38 EDTAGNAckman says Allergan CEO manipulated Valeant shares, CNBC reports
Subscribe for More Information
08:58 EDTAGNAllergan was pressured by AbbVie news, says BMO Capital
Subscribe for More Information
07:23 EDTAGNIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
October 15, 2014
15:00 EDTAGNShire-Allergan, AbbVie-Pfizer deals possible if merger scrapped, Bloomberg says
Subscribe for More Information
13:07 EDTAGNAllergan seeing arb-related selling pressure, says BMO Capital
Subscribe for More Information
08:54 EDTSCHWCharles Schwab says Q3 financial results impacted by 1c per share
Subscribe for More Information
08:52 EDTSCHWCharles Schwab reports Q3 balance sheets assets $105.6B
Subscribe for More Information
08:49 EDTSCHWCharles Schwab reports Q3 trading revenue $209M
Subscribe for More Information
08:48 EDTSCHWCharles Schwab reports Q3 EPS 24c, consensus 24c
Subscribe for More Information
October 14, 2014
08:36 EDTAMTDADP announces new business relationship with TD Ameritrade
Subscribe for More Information
07:59 EDTSCHW, ETFC, AMTDSchwab, Ameritrade look 'deeply undervalued,' says Deutsche Bank
Subscribe for More Information
07:15 EDTALKSBiotech Industry Organization to hold a summit
Subscribe for More Information
06:03 EDTAGNMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 13, 2014
10:26 EDTAMTDHigh option volume stocks
Subscribe for More Information
06:39 EDTAGNAllergan takeout value at or above $210 per share, says Leerink
Leerink believes Allergan's takeover value is now at or above $210 per share given the company's recent execution. After speaking with management, the firm says Allergan's upside in Q3 was driving by fundamentals, not cost cuts. It continues to view the "most likely and straightforward outcome" for Allergan as being an outright sale of the company. Leerink raised its price target for shares to $215 from $184 and keeps an Outperform rating on Allergan.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use